UY37907A - 3-PHENYLQUINAZOLIN-4 (3H) -UNES REPLACED AND ITS USES - Google Patents

3-PHENYLQUINAZOLIN-4 (3H) -UNES REPLACED AND ITS USES

Info

Publication number
UY37907A
UY37907A UY0001037907A UY37907A UY37907A UY 37907 A UY37907 A UY 37907A UY 0001037907 A UY0001037907 A UY 0001037907A UY 37907 A UY37907 A UY 37907A UY 37907 A UY37907 A UY 37907A
Authority
UY
Uruguay
Prior art keywords
compounds
preparation
phenylquinazolin
unes
replaced
Prior art date
Application number
UY0001037907A
Other languages
Spanish (es)
Inventor
Melissa Boultadakis Arapinis Dr
Eloisa Jimenez Nunez Dr
Julian Borissoff Dr
Michael Hahn Dr
Lisa Dietz Dr
Fabienne Zdenka Gaugaz Dr
Eckhard Bender Dr
Dieter Lang Dr
Anja Giese Dr
Kai Thede Dr
Ludwig Zorn Dr
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of UY37907A publication Critical patent/UY37907A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención abarca compuestos de 3-fenilquinazolin-4(3H)-ona sustituidos de la fórmula general (I) como se describe y se define en el presente, procedimientos para la preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en especial para el tratamiento y/o la profilaxis de diversas enfermedades inflamatorias y fibróticas del tracto respiratorio y de los pulmones, así como del cáncer de pulmón, como único agente o en combinación con otros ingredientes activos.The present invention encompasses substituted 3-phenylquinazolin-4 (3H) -one compounds of the general formula (I) as described and defined herein, processes for the preparation of said compounds, intermediate compounds useful for the preparation of said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for the preparation of pharmaceutical compositions for the treatment or prophylaxis of diseases, especially for the treatment and / or prophylaxis of various inflammatory and fibrotic diseases of the respiratory tract and of the lungs, as well as lung cancer, as the sole agent or in combination with other active ingredients.

UY0001037907A 2017-09-29 2018-09-27 3-PHENYLQUINAZOLIN-4 (3H) -UNES REPLACED AND ITS USES UY37907A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17193995 2017-09-29

Publications (1)

Publication Number Publication Date
UY37907A true UY37907A (en) 2019-04-30

Family

ID=59997232

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037907A UY37907A (en) 2017-09-29 2018-09-27 3-PHENYLQUINAZOLIN-4 (3H) -UNES REPLACED AND ITS USES

Country Status (4)

Country Link
AR (1) AR112840A1 (en)
TW (1) TW201922724A (en)
UY (1) UY37907A (en)
WO (1) WO2019063704A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021167883A1 (en) * 2020-02-21 2021-08-26 The Children's Medical Center Corporation Method for treating asthma or allergic disease
CN112370529B (en) * 2020-11-30 2022-11-11 中国药科大学 Compound preparation for treating pulmonary hypertension and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
JP4619545B2 (en) 1999-03-17 2011-01-26 アストラゼネカ アクチボラグ Amide derivatives
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
CN101001845A (en) * 2004-06-15 2007-07-18 阿斯利康(瑞典)有限公司 Substituted quinazolones as anti-cancer agents.
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2014234472A1 (en) 2013-03-20 2015-10-29 Bayer Pharma Aktiengesellschaft 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
US9682961B2 (en) * 2013-12-06 2017-06-20 Carna Biosciences, Inc. Quinazoline derivative

Also Published As

Publication number Publication date
AR112840A1 (en) 2019-12-18
TW201922724A (en) 2019-06-16
WO2019063704A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
NI201900041A (en) 1, 2, 4-TRIAZOLONES 2, 4, 5-TRISUSTITUIDAS
CL2019002255A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides.
DOP2019000117A (en) NEW DERIVATIVES OF QUINOLINA
CO2020001244A2 (en) Quinoline derivatives to treat helminth infections
UY37460A (en) 1,2,4-TRIAZOLONS WITH ANALATION IN 4 AND 5
CO2018010966A2 (en) New pyrazolopyrimidine derivatives
CO2019014484A2 (en) New azaquinoline derivatives
CO2019011877A2 (en) New bicyclic pyrazole derivatives
CO2020013876A2 (en) New quinoline derivatives
ECSP20008441A (en) DIHYDROOXADIAZINONES
UY37971A (en) SUBSTITUTED MACROCYCLIC INDOL DERITATES
UY38228A (en) TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
BR112019006880A2 (en) compounds and compositions for treating leishmaniasis and methods of diagnosis and treatment using the same
UY38816A (en) NEW DERIVATIVES OF ISOQUINOLINE
BR112018074381A2 (en) [8- (phenylsulfonyl) -3,8-diazabicyclo [3.2.1] oct-3-yl] (1h-1,2,3-triazol-4-yl) methanones
DOP2020000100A (en) NOVEL PYRAZOLO-PIRROLO-PYRIMIDINE DERIVATIVES AS P2X3 INHIBITORS
UY37907A (en) 3-PHENYLQUINAZOLIN-4 (3H) -UNES REPLACED AND ITS USES
CL2019001004A1 (en) Substituted derivatives of 6- (1h-pyrazol-1-yl) pyrimidin-4-amine and uses thereof.
BR112019017314A2 (en) pharmaceutical compositions for combination therapy
UY37530A (en) [4- (PHENYL SULFONYL) PIPERAZIN-1-IL] (1H-1,2,3-TRIAZOL-4-IL) METHANON
CL2019002315A1 (en) New medical use of compound iii.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231114